<DOC>
	<DOCNO>NCT00027664</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Thalidomide may stop growth cancer stop blood flow tumor . It yet know interferon alfa effective without thalidomide treat metastatic kidney cancer . PURPOSE : Randomized phase II trial compare effectiveness interferon alfa without thalidomide treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Interferon Alfa With Without Thalidomide Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety interferon alfa thalidomide patient metastatic renal cell carcinoma . - Compare relative toxicity interferon alfa without thalidomide patient . - Assess antiangiogenic effect thalidomide monitor angiogenesis-associated factor patient . - Compare , preliminary manner , efficacy interferon alfa without thalidomide patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive interferon alfa subcutaneously 3 time week oral thalidomide daily 12 week . - Arm II : Patients receive interferon alfa arm I . Treatment arm repeat every 12 week absence disease progression unacceptable toxicity . Patients arm II develop disease progression discontinue interferon alfa receive thalidomide arm I . Quality life assess baseline every 3 week study course . PROJECTED ACCRUAL : A total 90 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell carcinoma Measurable progressive disease , define nonirradiated marker lesion great 1 cm PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : More 12 week Hematopoietic : Neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT le 5 time ULN Renal : Creatinine clearance great 50 mL/min OR Edetic acid clearance great 40 mL/min Cardiovascular : No unstable angina myocardial infarction within past 6 month Other : No prior invasive malignancy except cervical intraepithelial neoplasia nonmelanomatous skin cancer No chronic neurological disease cause peripheral neuropathy No diabetes mellitus Not pregnant nursing Negative pregnancy test Fertile patient must use least one highly effective method least one additional effective method contraception female patient barrier contraception male patient least 2 week study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon alfa metastatic renal cell carcinoma Chemotherapy : No prior systemic chemotherapy metastatic renal cell carcinoma No concurrent cytotoxic therapy Endocrine therapy : No concurrent corticosteroid Radiotherapy : See Disease Characteristics Concurrent local radiotherapy symptomatic secondary site disease allow site use marker disease response Surgery : Not specify Other : No prior systemic treatment metastatic renal cell carcinoma No concurrent chronic medication know cause peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>